[{"id":"caca578c-aaca-49e5-a97d-ca67554ac90d","acronym":"CLINGLIO","url":"https://clinicaltrials.gov/study/NCT04250922","created_at":"2021-01-18T20:39:26.321Z","updated_at":"2024-07-02T16:34:59.713Z","phase":"Phase 2/3","brief_title":"LAM561 With RT and TMZ for Adults With Glioblastoma","source_id_and_acronym":"NCT04250922 - CLINGLIO","lead_sponsor":"Laminar Pharmaceuticals","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Minerval (idroxioleic acid)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 10/15/2024","primary_completion_date":" 10/15/2024","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2024-05-31"},{"id":"307b0a46-d1a9-4d91-8597-eafd1ed96804","acronym":"","url":"https://clinicaltrials.gov/study/NCT01792310","created_at":"2023-02-21T23:01:19.635Z","updated_at":"2024-07-02T16:35:55.057Z","phase":"Phase 1/2","brief_title":"A Phase 1/2A Study of LAM561 in Adult Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT01792310","lead_sponsor":"Laminar Pharmaceuticals","biomarkers":" GFAP","pipe":"","alterations":" ","tags":["GFAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Minerval (idroxioleic acid)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2023-02-21"}]